Metabolic control in patients with diabetic nephropathy;Stoffwechselführung und -kontrolle bei patienten mit diabetischer nephropathie

Arzneimitteltherapie

Volumn 27, Issue 6, 2009, Pages 199-205

  Hasslacher, Christoph ^a  

^a StJosefs Krankenhaus Heidelberg   (Germany)

Author keywords

Diabetes; Diabetic nephropathy; Insulin; Metabolic control; Oral antidiabetic drugs

Indexed keywords

ACARBOSE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIQUIDONE; HEMOGLOBIN A1C; INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; UNCLASSIFIED DRUG; VILDAGLIPTIN; XELEVIA;

CARBAMOYLATION; CATABOLISM; CELL CYCLE; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EXCRETION; ERYTHROCYTE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; KIDNEY FAILURE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

EID: 77953454975     PISSN: 07236913     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Gaede P, Vedel P, Larsen N, Jensen G, et al. Intensified multifactorial intervention and cardiovascular disease in patients with type 2 diabetes mellitus. N Engl J Med 2003;348:383-393 (Pubitemid 36159355)
2. Hasslacher C. Protektion der Nierenfunktion bei Diabetikern. Internist 2007;48:686-697 (Pubitemid 351285622)
3. Feld-Rasmussen B, Mathiesen ER, Jensen T, Lauritzen T, et al. Effect of improved metabolic control on loss of kidney function in type 1 (insulin-dependent) diabetic patients: an update of the Steno studies. Diabetologia 1991;34:164-170
4. The Diabetes Control and Complications Trial Research Group/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381-389
5. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23(Suppl 2):B21-9. (Pubitemid 30185774)
6. Gaede P, Vedel Pernille, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999;353:617-622 (Pubitemid 29087981)
7. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572
8. Holman RR, Sanjoy KP, Bethel MA, Matthews DR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
9. Manto A, Cotroneo P, Marra G, Magnani P, et al. Effect of intensive treatment in diabetic nephropathy in patients with type 1 diabetes. Kidney Int 1995;47:231-235
10. Mai-Szu Wu, Chun-Chen Yu, Chih-Wei Yang, et al. Poor pre-dialysis glycaemic control is a predictor of mortality in type 2 diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant 1997;12:2105-2110 (Pubitemid 27423249)
11. Wu MS, Yu CC, Yang CW, Wu CH, et al. Poor pre-dialysis glycaemic control is a predictor of mortality in type 2 diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant 1997;12:2105-2110 (Pubitemid 27423249)
12. Warram JH, Scott LJ, Hanna LS, Wantman M, et al. Progression of microalbuminuria to proteinuria in type 1 diabetes; nonlinear relationship with hyperglycemia. Diabetes 2000;49:94-98 (Pubitemid 30022929)
13. Ben-Ami H, Nagachandran P, Mendelson A, Edoute Y. Drug-induced hypoglycemia coma in 102 diabetic patients. Arch Intern Med 1999;159:281-384. (Pubitemid 29075648)
14. Hasslacher C, Wittmann W. Schwere Hypoglykämien bei Diabetikern mit eingeschränkter Nierenfunktion. Dtsch Med Wochenschr 2003;128:253-256
15. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002;137:25-33. (Pubitemid 34705373)
16. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and non-fatal lactic acidosis with metformin use in type 2 diabetes mellitus. Arch Intern Med 2003;163:2594-2602.
17. Thompson-Culkin K, Zussman B, Miller AK, Freed MI. Pharmacokinetics of rosiglitazone in patients with endage-renal disease. J Int Med Res 2002;30:391-399 (Pubitemid 34993563)
18. Eckland DA, Danhof M. Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol Diabetes 2000;108(Suppl 2):234-242
19. Jönsson A, Rydberg T, Sterner G, Melander A. Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. Eur J Clin Pharmacol 1998;53:429-435 (Pubitemid 28154743)
20. Rosenkranz R, Profozic V, Metelko Z, Mrzljak V, et al. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 1996;39:1617-1624 (Pubitemid 26397377)
21. Schumacher S, Abbasi I, Weise D, Hatorp V, et al. Single- and multiple-dose pharmacokinetics of repaghnide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol 2001;57:147-152 (Pubitemid 32449136)
22. Hasslacher C. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 2003;26:886-891
23. Inoue T, Shibahara N, Miyagawa K, Itahana R, et al. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol 2003;60:90-95 (Pubitemid 36975183)
24. Linnebjerg H, Kothare PA, Park S, Mace K, et al. Effect of renal impairement on the pharmacokinetics of exenatide. Br J Clin Pharmocol 2007;64:317-327 (Pubitemid 47283860)
25. Bergman AJ, Cote J, Yi B, Marbury T, et al. Effect of renal insufficiency on the pharmacokinetics of Sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007;30:1862-1864 (Pubitemid 47036366)
26. He YL, Flannery B, Wang Y, Campestrini J, et al. The influence of renal impairment on the pharmacokinetics of vildagliptin. Clin Pharm Ther 2007;81(Suppl 1):113-117
27. Svensson M, Yu ZW, Eriksson JW. A small reduction in glomerular filtration is accompanied by insulin resistance in type I diabetes patients with diabetic nephropathy. Eur J Clin Invest 2002;32:100-109 (Pubitemid 36232730)
28. Rave K, Heise T, Pfützner A, Heinemann L, et al. Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care 2001;24:886-890 (Pubitemid 33636064)
29. Vogt C, Dreyhaupt J, Hasslacher C. Einfluss der nachlassenden Nierenfunktion auf die Insulindosis bei Typ-1- und Typ-2-Diabetikern. Diabetologie 2006;1:311-318
30. Charlesworth JA, Kriketos AD, Jones JE, Erlich JH, et al. Insulin resistance and postprandial triglyceride levels in primary renal disease. Metabolism 2005;54:821-828 (Pubitemid 40725332)
31. Hasslacher C, Vogt C, Raupp D, Dreyhaupt J. Insulinbedarf bei Typ-1-Diabetikern mit nachlassender Nierenfunktion: Human-Insulin versus Analog-Insulin . Dtsch Med Wochenschr 2007;132:2500-2504
32. Joy MS, Cefalu WT, Hogan SL, Nachman PH. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis 2002;39:297-307. (Pubitemid 34174252)
33. Nakao T, Matsumoto H, Okada T, et al. Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Intern Med 1998;37:826-830 (Pubitemid 28550633)
34. Inaba M, Okuno S, Kumeda Y, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: Effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007;18:896-903. (Pubitemid 46434506)
35. Peacock TP, Shihabi ZK, Bleyer AJ, et al: Comparison of glycated albumin and hemoglobin A1c levels in diabetic subjects on hemodialysis. Kidney Int 2008;73:1062-1068 (Pubitemid 351543905)